Home / News Update  / Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m; Revenue Growth of 16.7% YoY with an EBITDA Margin of 20% US Revenues at Our Historic Quarter High of $70m

Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m; Revenue Growth of 16.7% YoY with an EBITDA Margin of 20% US Revenues at Our Historic Quarter High of $70m

Q1FY2025 Performance Highlights Revenues at ₹10,875m, Grew 16.7% YoY in line with FY25 Outlook Gross Margin improved by 264bps YoY to 61.3% EBITDA grew by 28.7% YoY to ₹2,170m with EBITDA margin at 20%,

Q1FY2025 Performance Highlights

  • Revenues at ₹10,875m, Grew 16.7% YoY in line with FY25 Outlook
  • Gross Margin improved by 264bps YoY to 61.3%
  • EBITDA grew by 28.7% YoY to ₹2,170m with EBITDA margin at 20%, a growth of 187bps YoY
  • US revenues at a historic high of $70m in Q1FY25, a growth of 24.5% YoY
  • Q1FY25 Adjusted PAT at ₹839m and Reported PAT at ₹683m
  • Reported EPS at ₹7.6 and Adj EPS at ₹9.1 for Q1FY25

 

Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q1FY25) ended June 30, 2024.

Financial Highlights (In ₹ m)

Particulars Q1FY25 Q1FY24 YoY Q4FY24 QoQ
Revenues 10,875 9,320 16.7% 10,583 2.8%
Gross Margin 6,671 5,470 21.9% 6,421 3.9%
Gross Margin % 61.3% 58.7% 264bps 60.7% 67bps
EBITDA 2,170 1,686 28.7% 2,040 6.4%
EBITDA % 20.0% 18.1% 187bps 19.3% 68bps
Adj PAT 839 295   670  
Reported PAT 683 (94)   104  

Adjusted PAT = PAT from continuing operations without JV share and exceptional items

Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook.

The company achieved critical thresholds of 20% EBITDA margin, ₹683m of reported PAT and 2.3x Debt/EBITDA ratio. We are confident of sustaining the momentum with continuous improvement in the quality of business.

The company has increased its focus on digitization, automation, and ESG for better compliance and business outcomes.”

Detailed investor communication on the performance of the Company along with an update on OneSource is attached.

medgatetoday@gmail.com

Review overview
NO COMMENTS

POST A COMMENT